Real-World Effectiveness and Satisfaction with Risankizumab for the Treatment of Psoriatic Arthritis in Biologic-Naïve Patients: A Population Survey in the United States and Europe
Biologic-naïve patients with PsA starting RZB demonstrated significant and meaningful improvements in joint symptoms, pain, and fatigue in real-world settings. High levels of satisfaction with RZB for disease control were reported by both patients and physicians.
Authors
- Manish Patel (ORCID: https://orcid.org/0009-0002-6139-6873)
- Andrew J.K. Östör (ORCID: https://orcid.org/0000-0002-7929-4827)
- Jamie Vora (ORCID: https://orcid.org/0000-0002-6922-5617)
- Gary Milligan (ORCID: https://orcid.org/0000-0002-1427-3339)
- Jessica A. Walsh (ORCID: https://orcid.org/0000-0002-4563-0845)
- Xiaolan Ye (ORCID: https://orcid.org/0000-0001-7620-9642)
- Christopher D. Saffore (ORCID: https://orcid.org/0000-0003-0396-2646)
- Isabel Truman (ORCID: https://orcid.org/0000-0002-6055-2902)
- Mark Edwards (ORCID: https://orcid.org/0000-0003-2584-0834)
- Ana Biljan
Institutions
- Australian National University (AU)
- University of Utah (US)
- AbbVie (United States) (US)
- Adelphi Group (United Kingdom) (GB)
Publication Details
- Journal
- Rheumatology and Therapy
- Published
- 2025-10-23
- DOI
- https://doi.org/10.1007/s40744-025-00801-6
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00